* Aprea Therapeutics Inc APRE.OQ reported a quarterly
adjusted
loss of 67 cents per share for the quarter ended in March,
higher than the same quarter last year, when the company
reported EPS of $-1.34. The mean expectation of three analysts
for the quarter was for a loss of 78 cents per share. Wall
Street expected results to range from -80 cents to -75 cents per
share.
* Reported revenue was zero; analysts expected zero.
* Aprea Therapeutics Inc's reported EPS for the quarter was
a loss
of 67 cents.
* The company reported a quarterly loss of $2.81 million.
* Aprea Therapeutics Inc shares had fallen by 16.4% this
quarter and gained 18.9% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 288.2% in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Aprea
Therapeutics Inc is $16.00
This summary was machine generated from LSEG data May 14 at
02:38 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.78 -0.67 Beat
Dec. 31 2023 -0.77 -0.92 Missed
Sep. 30 2023 -1.16 -0.86 Beat
Jun. 30 2023 -1.42 -0.87 Beat